Galecto Marge FCF

Que fait Galecto ? Galecto, Inc. develops small molecule therapeutics targeting galectin-3 and LOXL2 for cancer and fibrotic diseases. The company focuses on GB0139 for Idiopathic Pulmonary Fibrosis (IPF), GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are designed to address biological processes central to these conditions. The firm targets medical professionals and healthcare institutions seeking novel treatments for fibrotic and oncological disorders. Galecto's revenue streams come from the development and potential future commercialization of its therapeutic candidates. The company is a clinical-stage biotechnology firm, meaning it is currently in the development phase and has not yet generated revenue from product sales. The primary buyers of Galecto's products will be healthcare providers and pharmaceutical distributors once the drugs are approved and marketed. The company's product pipeline includes GB0139 for IPF, GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are developed as small molecule inhibitors targeting specific biological processes. Galecto's focus on clinical-stage development indicates that it is still in the research and testing phase, with no current revenue from product sales. Galecto est l'une des entreprises les plus populaires sur Eulerpool.